retatrutide dosing protocol Dosage & Guide: Titration, Missed Doses, Taper Retatrutide Dosing: Weekly Injections, Clinical

After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )

If muscle pain persists despite optimization of all modifiable factors, a trial of semaglutide or another GLP-1 agonist may be reasonable

For individuals already focusing on foundational nutrition through options like plant based protein powder adding targeted antioxidant support can further strengthen overall cellular resilience and metabolic balance

References (1) Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C

Cardiovascular and renal outcomes with empagliflozin in heart failure